Concord Drugs Standalone March 2024 Net Sales at Rs 14.47 crore, up 25.35% Y-o-Y
June 07, 2024 / 12:15 IST
Reported Standalone quarterly numbers for Concord Drugs are: Net Sales at Rs 14.47 crore in March 2024 up 25.35% from Rs. 11.54 crore in March 2023. Quarterly Net Loss at Rs. 0.35 crore in March 2024 down 609.95% from Rs. 0.07 crore in March 2023. EBITDA stands at Rs. 0.19 crore in March 2024 down 74.32% from Rs. 0.74 crore in March 2023. Concord Drugs shares closed at 37.02 on June 06, 2024 (BSE) and has given 3.01% returns over the last 6 months and 37.26% over the last 12 months.
| Concord Drugs | | Standalone Quarterly Results | in Rs. Cr. |
|
Story continues below Advertisement
| Mar'24 | Dec'23 | Mar'23 | | Net Sales/Income from operations | 14.47 | 12.62 | 11.54 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 14.47 | 12.62 | 11.54 | | EXPENDITURE | | Consumption of Raw Materials | 12.79 | 10.44 | 9.44 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -0.09 | 0.01 | 0.07 | | Power & Fuel | -- | -- | -- | | Employees Cost | 1.25 | 1.20 | 1.02 | | Depreciation | 0.39 | 0.38 | 0.31 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 0.32 | 0.41 | 0.27 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -0.20 | 0.18 | 0.43 | | Other Income | 0.00 | -- | 0.00 | | P/L Before Int., Excpt. Items & Tax | -0.20 | 0.18 | 0.43 | | Interest | 0.38 | 0.43 | 0.42 | | P/L Before Exceptional Items & Tax | -0.58 | -0.26 | 0.02 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -0.58 | -0.26 | 0.02 | | Tax | -0.22 | -0.02 | -0.05 | | P/L After Tax from Ordinary Activities | -0.35 | -0.24 | 0.07 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -0.35 | -0.24 | 0.07 | | Equity Share Capital | 10.00 | 10.00 | 9.32 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -0.35 | -0.24 | 0.07 | | Diluted EPS | -0.35 | -0.24 | 0.07 | | EPS After Extra Ordinary | | Basic EPS | -0.35 | -0.24 | 0.07 | | Diluted EPS | -0.35 | -0.24 | 0.07 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
